氘可来昔替尼(Deucravacitinib)在哪里能买到?

Purchasing channels for Deucravacitinib

Deucravacitinib will be launched in China in October 2023. Due to its short time on the market, the drug is not currently easy to buy, and no relevant price information has been found on the Internet. Patients in need can consult local hospital pharmacy staff to see if it is available.

The Bangladeshi version of Deucravacitinib is affected by various factors and is not fixed. Currently, the price we know is about $550 per box, and the specification is 6mg*30 tablets.

The Bangladeshi version of Deucravacitinib is not available in mainland China. The Bangladeshi version is not available in domestic hospital pharmacies. Patients can go to Bangladesh to buy it, but the journey is long, the risk is high, and the financial burden is heavy.

Some e-commerce platforms or online pharmacies that specialize in drug sales provide convenient ways to purchase drugs. Patients only need to search for deuterated coxitinib on the platform to find it. However, you need to purchase from formal and qualified channels to prevent being deceived.

Patients can also obtain it through the help of domestic professional overseas medical service institutions. Patients can calculate the required quantity and cost of this product based on their own circumstances. Deucravacitinib is taken orally at 6 mg once a day, and one box can last about a month. This method is cost-effective and suitable for long-term medication. The medication can be mailed to your home and is guaranteed to be genuine. However, it is recommended to consult customer service staff for the specific cost and acquisition process.

Efficacy of Deucravacitinib

Comparing oral selective ectopic tyrosine kinase 2 inhibitors Deucravacitinib, an oral selective ectopic tyrosine kinase 2 inhibitor, compared with placebo and apremilast in adults with moderate to severe plaque psoriasis.

Research Methods

In the double-blind phase 3 POETYK In the PSO-1 trial (NCT03624127), participants were randomized 2:1:1 in a 2:1:1 ratio to receive 6 mg of deucravacitinib per day (332 people), placebo (166 people), or 30 mg of apremilast twice daily (168 people) for 52 weeks.

Trial results

At week 16, the response rate of Deucravacitinib was significantly higher than that of placebo or Apremilast in terms of PASI 75 and sPGA 0/1. Efficacy improved after week 16 and was maintained through week 52. The incidence rate with Deucravacitinib was similar to placebo and apremilast.

Trial Conclusion

Deucravacitinib was superior to placebo and apremilast on multiple efficacy endpoints, and was well tolerated in patients with moderate to severe plaque psoriasis.

Recommended hot articles:

References

Armstrong AW, Gooderham M, Warren RB, Papp KA, Strober B, Thaçi D, Morita A, Szepietowski JC, Imafuku S, Colston E, Throup J, Kundu S, Schoenfeld S, Linaberry M, Banerjee S, Blauvelt A. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023 Jan;88(1):29-39. doi: 10.1016/j.jaad.2022.07.002. Epub 2022 Jul 9. PMID: 35820547.